Q3 2022 Results

NEW INDICATIONS Company overview Financial performance Financial review 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials Novartis submission schedule New Molecular Entities: Lead and supplementary indications LEAD INDICATIONS References Abbreviations 2022 2023 2024 ensovibep Lead iptacopan Lead JDQ443 Lead 2025 ligelizumab ≥2026 Lead 177 Lu-NeoB Lead iscalimab Lead SKO136 COVID19 LNP023 PNH JDQ443 QGE031 AAA603 CFZ533 MIJ821 Acute depression Lead 2/3L NSCLC (mono) Food allergy Multiple Solid Tumors Sjögren's syndrome sabatolimab Lead NIS793 Lead branaplam¹ Lead ianalumab Lead PPY9883 Lead MBG453 1L Pancreatic cancer LMI070 VAY736 Geographic atrophy HR-MDS Huntington's disease Sjögren's syndrome remibrutinib Lead pelacarsen Lead cipargamin Lead libvatrep Lead TNO155 Lead LOU064 TQJ230 KAE609 SAF312 Solid tumors CSU CVRR-Lp(a) Malaria severe COSP YTB3231 Lead ganaplacide Lead LNA043 Lead 2L Diffuse large B-cell lymphoma KAF156 Knee osteoarthritis Malaria uncomplicated gevokizumab Lead LXE408 Lead VPM087 Visceral leishmaniasis 1st line CRC tislelizumab LCM Pluvicto LCM Pluvicto LCM Scemblix LCM cipargamin LCM ianalumab LCM remibrutinib LCM VDT482 AAA617 AAA617 ABL001 KAE609 VAY736 LOU064 NSCLC mCRPC, Pre-taxane mHSPC CML 1L Malaria uncomplicated SLE Sjögren's syndrome iptacopan LCM tislelizumab LCM iptacopan LCM JDQ443 LCM LNP023 VDT482 LNP023 JDQ443 iptacopan LNP023 LCM remibrutinib LCM LOU064 C3G 1L Small Cell Lung Cancer aHUS NSCLC (combo) iMN Multiple sclerosis iptacopan LCM ianalumab LCM sabatolimab LCM tislelizumab LCM LNP023 VAY736 MBG453 VDT482 IgAN AIH Unfit AML Adj/Neo adj NSCLC tislelizumab LCM ianalumab LCM Scemblix LCM tislelizumab LCM VDT482 VAY736 ABL001 VDT482 1L Gastric Cancer Lupus Nephritis CML, 2L, pediatrics 1L Urothelial Cell Carcinoma tislelizumab LCM VDT482 1L ESCC tislelizumab LCM VDT482 Localized ESCC tislelizumab LCM VDT482 1L Hepatocellular Carcinoma tislelizumab LCM VDT482 1L Nasopharyngeal Carcinoma 1. Development strategy being updated. 2. Plan update on-going. 3. Gyroscope acquisition. 41 Investor Relations | Q3 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation